Overview

Study Evaluating Safety And Tolerability, Solid Tumor

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
Phase:
Phase 1
Details
Lead Sponsor:
Puma Biotechnology, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel